Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P36575
UPID:
ARRC_HUMAN
Alternative names:
Cone arrestin; Retinal cone arrestin-3; X-arrestin
Alternative UPACC:
P36575; B5B0B9; Q5JT23; Q5JT24; Q6IBF5; Q96EN2
Background:
Arrestin-C, also known as Cone arrestin or Retinal cone arrestin-3, plays a pivotal role in retina-specific signal transduction, potentially binding to photoactivated-phosphorylated red/green opsins. This protein, encoded by the gene with accession number P36575, is integral to the proper functioning of visual processes.
Therapeutic significance:
Arrestin-C is linked to Myopia 26, X-linked, female-limited, a condition characterized by early onset high myopia and unique tigroid fundus changes. Understanding the role of Arrestin-C could open doors to potential therapeutic strategies for this and related visual disorders.